The Khavinson short-peptide programme: 40 years on

Vladimir Khavinson's St Petersburg Institute of Bioregulation and Gerontology has run a continuous short-peptide research programme for four decades, producing the largest single body of work on short bioregulatory peptides — including Epitalon (AEDG, tetrapeptide), Pinealon (EDR, tripeptide) and a substantial catalogue of related compounds aimed at tissue-specific gene regulation.

The programme rests on a coherent theoretical framework: that short peptides derived from tissue extracts can act as gene-regulatory signals selective for the tissue of origin. Each compound in the catalogue is positioned as the 'active fraction' of a specific tissue extract — pineal for Epitalon, neural tissue for Pinealon, thymus for the thymic-cytomedine peptides — and is hypothesised to bind specific DNA sequence motifs in promoter regions of relevant genes.

The strengths of the programme are its internal consistency and the depth of the rodent toxicology dataset. Across decades of work, Khavinson and colleagues have reported reproducible effects on lifespan, tumour incidence, biomarker normalisation and behavioural performance in aged animals. Safety profiles have been favourable.

The weaknesses are also well-known: independent replication outside the original group is limited; the DNA-binding mechanism has not been comprehensively characterised by external chromatin-immunoprecipitation work; and the human evidence base consists primarily of open-label observational studies in Russian-language gerontology journals rather than modern randomised controlled trials.

The honest assessment in 2026 is that the Khavinson programme represents a substantial but partially-isolated body of preclinical work that deserves more independent attention than it has received. The case for further independent research is straightforward: if the gene-regulatory short-peptide hypothesis holds up under modern molecular-biology methods, the implications for both ageing biology and broader gene-regulatory pharmacology are significant. If it does not, the field benefits from knowing.